Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + cisplatin + 5-fluorouracil + folinic acid
- Development stage
- Unknown
- Lead developer
- CONKO-Studiengruppe
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Gemcitabine + cisplatin + 5-fluorouracil + folinic acid is an investigational combination chemotherapy regimen evaluated by the German CONKO-Studiengruppe, specifically in the CONKO-101 Phase 2 clinical trial. This regimen was developed for the treatment of patients with inoperable esophageal cancer, including both squamous cell carcinoma and adenocarcinoma. The combination leverages multiple mechanisms: gemcitabine acts as a nucleoside analog that inhibits DNA synthesis and ribonucleotide reductase; cisplatin is a platinum-based agent that induces DNA cross-linking; 5-fluorouracil (5-FU) is a pyrimidine analog that inhibits thymidylate synthase; and folinic acid is used as a biochemical modulator to enhance the binding and efficacy of 5-FU. The trial aimed to achieve a freedom of progression rate of over 60% in this patient population.
- Other names
- Gemcitabine-Cisplatin-5-FU-Folinic AcidGemcitabine-Cisplatin5-FU-Folinic AcidGemcitabine-Cisplatin 5-FU-Folinic AcidCONKO-101 regimenCONKO101 regimenCONKO 101 regimenGemcitabine-CONKO-Studiengruppe-esophageal cancer
02
Targets
TS (Thymidylate synthase)DNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on gemcitabine + cisplatin + 5-fluorouracil + folinic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + cisplatin + 5-fluorouracil + folinic acid.